Alkanolamines and Fatty Alkanolamides Group

Information sheet

• Alkanolamines and Fatty Alkanolamides Group

These substances were identified for action under the Chemicals Management Plan (CMP). This screening assessment focuses on 11 substances referred to collectively as the Alkanolamines and Fatty Alkanolamides Group.

• Summary of publications
• Timelines
• Background

Summary of publications

Substance group	Sub-group	CAS RN	Acronym	DSL name	Draft screening assessment	Proposed conclusion on section 64 criteria	Follow-up activities
Alkanolamines and Fatty Alkanolamides Group	1	141-43-5	MEA	Ethanol, 2-amino-	HTML	Do not meet	None planned at this time
	1	100-37-8	DEEA	Ethanol, 2-(diethylamino)-
	1	142-78-9	LME	Dodecanamide, N-(2-hydroxyethyl)-
	2A	111-42-2	DEA	Ethanol, 2,2'-iminobis-			Under consideration
	2A	120-40-1	LDE	Dodecanamide, N,N-bis(2-hydroxyethyl)-
	2A	68603-42-9Footnote a	CDE	Amides, coco, N,N-bis(hydroxyethyl)
	2B	61791-31-9Footnote a	CADEA	Ethanol, 2,2'-iminobis-, N-coco alkyl derivs.			None planned at this time
	2B	61791-44-4Footnote a	TADEA	Ethanol, 2,2'-iminobis-, N-tallow alkyl derivs.
	3	102-71-6	TEA	Ethanol, 2,2',2''-nitrilotris-			Under consideration
	3	122-20-3Footnote b	TIPA	2-Propanol, 1,1',1''-nitrilotris-			None planned at this time
	3	85204-21-3 Footnote a,Footnote c	BATEA	2-Butenoic acid, 4-[(2-ethylhexyl)amino]-4-oxo-, (Z)-, compd. with 2,2',2''-nitrilotris[ethanol] (1:1)
Footnote a This CAS RN is a UVCB (unknown or variable composition, complex reaction products, or biological materials). Return to footnote a referrer Footnote b This substance was not identified under subsection 73(1) of the Canadian Environmental Protection Act, 1999 (CEPA 1999) but was included in this assessment as it was considered a priority on the basis of other human health concerns. Return to footnote b referrer Footnote c This substance was not identified under subsection 73(1) of CEPA 1999 but was included in this assessment as it was considered a priority as a result of the approach described for identification of risk assessment priorities. Return to footnote c referrer

Timelines

Date	Activity
July 2021	Anticipated publication of the final screening assessment.
July 18, 2020	Publication and start of 60-day public comment period on the draft screening assessment (including follow-up activities for DEA, LDE, CDE and TEA). The related notice was published in the Canada Gazette, Part I: Vol. 154, No. 29.

Background

The 7 alkanolamine substances (CAS RNs 141-43-5, 100-37-8, 111-42-2, 61791-31-9, 61791-44-4, 102-71-6 and 122-20-3) in this screening assessment were originally referred to as the Alkanolamines Group under the CMP, while the 3 fatty alkanolamides (CAS RNs 120-40-1, 142-78-9, 68603-42-9) were moved to this group from the Fatty Amides Group as they potentially contain residual alkanolamines. One substance in this group, BATEA (CAS RN 85204-21-3), was included in this assessment because it was determined to be a priority as a result of the approach described for the identification of risk assessment priorities (IRAP).